Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

September 01, 1994; Volume 22,Issue 5
  • You have access
    Role of cytochrome P450 2E1 in the metabolism of 1,1,2,3,3,3-hexafluoropropyl methyl ether.
    U Köster, P Speerschneider, R Kerssebaum, H Wittmann and W Dekant
    Drug Metabolism and Disposition September 1994, 22 (5) 667-672;
  • You have access
    1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU) modulates rat liver microsomal cyclophosphamide and ifosphamide activation by suppressing cytochrome P450 2C11 messenger RNA levels.
    T K Chang, H Chen and D J Waxman
    Drug Metabolism and Disposition September 1994, 22 (5) 673-679;
  • You have access
    Role of Kupffer cells in storage and metabolism of benzo(a)pyrene in the liver.
    Z Zhong, M Goto, T Hijioka, H Oide, F C Kauffman and R G Thurman
    Drug Metabolism and Disposition September 1994, 22 (5) 680-687;
  • You have access
    cDNA-directed expression of human cytochrome P450 CYP3A4 using baculovirus.
    J T Buters, K R Korzekwa, K L Kunze, Y Omata, J P Hardwick and F J Gonzalez
    Drug Metabolism and Disposition September 1994, 22 (5) 688-692;
  • You have access
    Physiological disposition of L-663,581, a partial agonist of the benzodiazepine receptor, in laboratory animals.
    I W Chen and J H Lin
    Drug Metabolism and Disposition September 1994, 22 (5) 693-699;
  • You have access
    Oxidation of R(+)- and S(-)-carvedilol by rat liver microsomes. Evidence for stereoselective oxidation and characterization of the cytochrome P450 isozymes involved.
    M Fujimaki
    Drug Metabolism and Disposition September 1994, 22 (5) 700-708;
  • You have access
    Pharmacokinetics of HIV protease inhibitor DMP 323 in rats and dogs.
    M F Grubb, Y N Wong, D L Burcham, P L Saxton, C Y Quon and S M Huang
    Drug Metabolism and Disposition September 1994, 22 (5) 709-712;
  • You have access
    Studies on the glucuronidation of dopamine D-1 receptor antagonists, SCH 39166 and SCH 23390, by human liver microsomes.
    T R Tephly, B Coffman, P Styczynski, G Rios, D M Charkowski, M Vanrollins, R D McQuade and C E Tedford
    Drug Metabolism and Disposition September 1994, 22 (5) 713-718;
  • You have access
    Stereoselective hydroxylation of tacrine in rats and humans.
    W D Hooper, W F Pool, T F Woolf and J Gal
    Drug Metabolism and Disposition September 1994, 22 (5) 719-724;
  • You have access
    Sulfation of acetaminophen and acetaminophen-induced alterations in sulfate and 3'-phosphoadenosine 5'-phosphosulfate homeostasis in rats with deficient dietary intake of sulfur.
    Z Gregus, H J Kim, C Madhu, Y Liu, P Rozman and C D Klaassen
    Drug Metabolism and Disposition September 1994, 22 (5) 725-730;
  • You have access
    Detoxication of the 2',3'-epoxide metabolites of allylbenzene and estragole. Conjugation with glutathione.
    G Luo and T M Guenthner
    Drug Metabolism and Disposition September 1994, 22 (5) 731-737;
  • You have access
    Novel carbamate metabolites of mofegiline, a primary amine monoamine oxidase B inhibitor, in dogs and humans.
    J Dow, F Piriou, E Wolf, B D Dulery and K D Haegele
    Drug Metabolism and Disposition September 1994, 22 (5) 738-749;
  • You have access
    Formation of toxic metabolites from thiabendazole and other thiazoles in mice. Identification of thioamides as ring cleavage products.
    T Mizutani, K Yoshida and S Kawazoe
    Drug Metabolism and Disposition September 1994, 22 (5) 750-755;
  • You have access
    Metabolism of methoxyphenamine in vitro by a CYP2D6 microsomal preparation.
    R T Coutts, O O Bolaji, P Su and G B Baker
    Drug Metabolism and Disposition September 1994, 22 (5) 756-760;
  • You have access
    Inter-individual differences of 4-[4-(4-methylphenyl)-phenylmethoxy-1-piperidinyl]butyric acid disposition in rats: possible involvement of genetic polymorphism.
    E Takahara, O Nagata, H Kato, S Ohta and M Hirobe
    Drug Metabolism and Disposition September 1994, 22 (5) 761-769;
  • You have access
    Pharmacokinetics of dapsone and amino acid prodrugs of dapsone.
    N L Pochopin, W N Charman and V J Stella
    Drug Metabolism and Disposition September 1994, 22 (5) 770-775;
  • You have access
    Effects of diltiazem on the disposition and metabolism of the enantiomers of propranolol in the dog during multiple oral dosing.
    S M Lankford, C Maskasame and S A Bai
    Drug Metabolism and Disposition September 1994, 22 (5) 776-787;
  • You have access
    The in vitro hepatic metabolism of ABT-418, a cholinergic channel activator, in rats, dogs, cynomolgus monkeys, and humans.
    A D Rodrigues, J L Ferrero, M T Amann, G A Rotert, S P Cepa, B W Surber, J M Machinist, N R Tich, J P Sullivan and D S Garvey
    Drug Metabolism and Disposition September 1994, 22 (5) 788-798;
  • You have access
    Stable expression of a human liver UDP-glucuronosyltransferase (UGT2B15) with activity toward steroid and xenobiotic substrates.
    M D Green, E M Oturu and T R Tephly
    Drug Metabolism and Disposition September 1994, 22 (5) 799-805;
  • You have access
    Inhibition of p-nitrophenol hydroxylase in rat liver microsomes by small aromatic and heterocyclic molecules.
    M B Hargreaves, B C Jones, D A Smith and A Gescher
    Drug Metabolism and Disposition September 1994, 22 (5) 806-810;
  • You have access
    FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4.
    B V Karanam, S H Vincent, D J Newton, R W Wang and S H Chiu
    Drug Metabolism and Disposition September 1994, 22 (5) 811-814;
  • You have access
    Carbonyl reduction of 6-tert-butyl-2,3-epoxy-1,4-benzoquinone, a metabolite of 3-tert-butyl-4-hydroxyanisole, by rat liver microsomes and cytosol.
    K Tajima, M Hashizaki, K Yamamoto and T Mizutani
    Drug Metabolism and Disposition September 1994, 22 (5) 815-818;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 22, Issue 5
1 Sep 1994
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics